Anti PD-1 protitelesa

Anti PD-1 protitelesa

Protein programirane celične smrti 1:PD-1 (Programmed cell death protein 1) je transmembranski protein, ki je izražen na celicah T, B, NK ter monocitih in dendritičnih celicah. Vezava med PD-1 in njegovimi ligandi zavira tumorsko celično apoptozo, spodbuja izčrpanost T-celic in preprečuje aktiven an...

Full description

Bibliographic Details
Main Author:	Janja Ocvirk
Format:	Article
Language:	Slovenian
Published:	Institute of Oncology Ljubljana 2017-12-01
Series:	Onkologija
Subjects:	imunoterapija anti-PD-1 protitelesa zaviralci receptorjev
Online Access:	https://revijaonkologija.si/Onkologija/article/view/52

Similar Items

Imunoterapija: Nova zdravila, drugačni sopojavi
by: Tanja Ovčariček
Published: (2018-07-01)

Imunoterapija pri ploščatoceličnem karcinomu glave in vratu
by: Gaber Plavc, et al.
Published: (2021-05-01)

APPEARANCE OF AUTOIMMUNE DISEASES IN PATIENTS WITH ENDOMETRIOSIS
by: Nina Slabe, et al.
Published: (2018-02-01)

Zaviralci angiogeneze v zdravljenju možganskih tumorjev
by: Janja Ocvirk
Published: (2009-12-01)

AUTOIMMUNE ASPECTS OF PREMATURE OVARIAN FAILURE
by: Helena Meden Vrtovec, et al.
Published: (2018-02-01)

Karcinom Merklovih celic
by: Janja Ocvirk
Published: (2018-09-01)

Vloga imunskega sistema in imunoterapija pri trojno negativnem raku dojk
by: Cvetka Grašič Kuhar
Published: (2020-05-01)

Stranski učinki ob zdravljenju rakavih bolezni z zaviralci tirozinskih kinaz
by: Marina Mencinger
Published: (2018-07-01)

Mesto imunoterapije pri zdravljenju raka
by: Cvetka Grašič-Kuhar
Published: (2017-12-01)

Letno srečanje ASCO
by: Tanja Čufer
Published: (2015-06-01)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
by: Yaxiong Zhang, et al.
Published: (2018-12-01)

Imunoterapija prvič tudi za zdravljenje lokalno napredovalega nedrobnoceličnega pljučnega raka
by: Karmen Stanič, et al.
Published: (2017-12-01)

COMPARISON OF EFFICACY AND TOLERABILITY OF TWO SELECTIVE M3 RECEPTOR ANTAGONISTS SOLIFENACIN AND DARIFENACIN IN WOMEN WITH OVERACTIVE BLADDER – THE SOLIDAR STUDY
by: Igor But, et al.
Published: (2018-02-01)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
by: Andrea Botticelli, et al.
Published: (2021-08-01)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
by: Angelo Borsarelli Carvalho Brito, et al.
Published: (2021-04-01)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
by: Kohei Fujita, et al.
Published: (2020-01-01)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
by: Martin Rao, et al.
Published: (2017-03-01)

Adoptivna celična terapija in limfociti T z izraženimi himernimi antigenskimi receptorji
by: Uroš Rajčević
Published: (2020-09-01)

Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances
by: Semir Vranic
Published: (2017-08-01)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
by: Giuseppe Bellastella, et al.
Published: (2021-08-01)

The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
by: Li Y, et al.
Published: (2021-02-01)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
by: Sonam Puri, et al.
Published: (2020-01-01)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
by: Chaoxu Zhang, et al.
Published: (2020-05-01)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
by: Alessio Cortellini, et al.
Published: (2019-02-01)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
by: Long Ma, et al.
Published: (2021-08-01)

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
by: Chunmeng Wang, et al.
Published: (2021-07-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
by: Andrea Botticelli, et al.
Published: (2018-08-01)

A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder
by: Xiaoxiao Wang, et al.
Published: (2021-06-01)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
by: Feifei Teng, et al.
Published: (2020-09-01)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
by: Edouard Dantoing, et al.
Published: (2021-06-01)

Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
by: Xuanyi Wang, et al.
Published: (2020-04-01)

Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
by: Xue W, et al.
Published: (2019-03-01)

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage
by: Yuan Hong, et al.
Published: (2021-03-01)

Anti-PD-1-Induced Hidradenitis Suppurativa
by: Alexia Maillard, et al.
Published: (2021-02-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)